IRVINE, CA, Feb. 26, 2014 /PRNewswire/ - The PAWS Pet Company, Inc. (OTCQB:PAWS), is pleased to announce that February orders at its Mesa Pharmacy, Inc. (Mesa) subsidiary have continued to increase inline with expectations and have generated gross revenues, excluding allowances for returns and discounts, exceeding $6.5 Million Dollars. "We are currently filling prescriptions for transdermal topical pain medications of approximately $400,000 dollars per day". Stated Andrew Do, Mesa's President and Registered Pharmacist.
As controlled narcotic medications become more problematic and laws continue to limit options for physicians to control pain, other alternatives are being considered. Mesa's non-narcotic trans-dermal formulations for pain management are becoming more popular for managing pain suffered by injured workers. Mesa is continuing its plan to increase staff for the surge in orders that has occurred as a result of its recent agreement with Trestles Pain Specialists LLC.
About The PAWS Pet Company, Inc. The PAWS Pet Company, Inc. is undergoing a transition from the pet space to the pharmaceutical space. This exciting transition strategy has been developed to take advantage of the changes underway in traditional medical services. PAWS believes that great opportunities exist in pharmaceuticals and how they are delivered to the public. About Mesa Pharmacy, Inc. Mesa focuses on providing custom compounded non-narcotic, transdermal topical pain medications that are marketed to industrial health physicians and clinics. Mesa compounds a series of topical prescription medications, in different strengths, that provide the pain relief doctors seek and that have a very low propensity for addiction. As a result, physicians and insurers need not worry about treating an injured worker and winding up having to treat that worker's potential addiction to pain killing narcotics.
For more information on The PAWS Pet Company go to: www.thepawspetcompany.comForward-Looking Statements The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements that are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995).
The actual results may differ materially from those described or contemplated and consequently, you should not rely on these forward-looking statements as predictions of future events. Certain of these risks and uncertainties are discussed in the reports we filed with the SEC. SOURCE The PAWS Pet Company, Inc.
Market Data 
Markets 
AI
